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ABSTRACT (249 words) 
Rationale: Critical illness may be associated with increased bone turnover 
and loss of bone mineral density. Prospective evidence describing long-term 
changes in bone mineral density after critical illness is needed to further 
define this relationship. 
 
Objectives: To measure the change in bone mineral density and bone 
turnover markers in patients one year after critical illness compared to 
population-based controls. 
 
Methods: We studied adult patients admitted to a tertiary intensive care unit 
(ICU) and requiring mechanical ventilation for at least 24 hours. We measured 
clinical characteristics, bone turnover markers and bone mineral density 
during admission and one year after ICU discharge. We compared change in 
bone mineral density to age and sex-matched controls from the Geelong 
Osteoporosis Study.  
 
Measurements and Main Results: Sixty-six patients completed bone mineral 
density testing. Bone mineral density decreased significantly in the year after 
critical illness at both femoral neck and anterior-posterior spine site. The 
annual decrease was significantly greater in the ICU cohort compared to 
matched controls (anterior-posterior spine -1.59%, 95% CI -2.18, -1.01, p< 
0.001, femoral neck -1.20%, 95% CI -1.69, -0.70, p <0.001). There was a 
significant increase in 10-year fracture risk for major fractures (4.85+5.25 vs 
5.50+5.52, p<0.001) and hip fractures (1.57+2.40 vs 1.79+2.69, p=0.001). 
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The pattern of bone resorption markers was consistent with accelerated bone 
turnover. 
 
Conclusions: Critically ill patients experience a significantly greater decrease 
in bone mineral density in the year after admission compared to population-
based controls. Their bone turnover biomarkers pattern is consistent with 
increased rate of bone loss. 
 
Keywords: Critical illness, long-term outcomes, osteoporosis, fracture, bone 
loss, bone mineral density, bone turnover markers.
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INTRODUCTION  
Compared to their pre-illness status and general population controls, survivors 
of critical illness face increased mortality1-4, physical 1,5-7, and cognitive 
impairment8-10, and psychological distress11-13. A specific area where critical 
illness may adversely affect the well-being of survivors relates to an increased 
risk of fragility fracture 14,15. However, unlike other aspects of post-critical 
illness recovery, this risk has not been repeatedly explored. 
 
Osteoporosis is a chronic progressive disease and major public health 
issue16, characterized by low bone mass, micro-architectural bone disruption, 
and skeletal fragility leading to fracture17. The lifetime risk of osteoporotic 
spine, hip, or wrist fracture is 30-40% in developed countries, and the lifetime 
risk of hip fracture is one in six in white females18, with significant associated 
health burden of mortality, morbidity, and cost19,20. However, as few as 13-
27% of patients with osteoporosis are treated following a fragility fracture, 
suggesting osteoporosis remains an under diagnosed disease21,22.  
 
Critical illness, with its associated immobilization, inflammation, and endocrine 
dysfunction, may be associated with increased bone turnover 23-32, loss of 
bone mineral density (BMD)33, and an increased risk of fragility fracture14,15. 
Critical illness associated increase in bone turnover and subsequent fragility 
fracture could contribute to long-term morbidity and mortality, and is a 
potential target for intervention34. However, prospective evidence describing 
the relationship between critical illness and bone loss is needed to establish 
the rationale for intervention. Accordingly, the aim of this study was to 
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describe the changes in BMD and bone turnover markers (BTMs) in men and 
women in the year after critical illness, compared to population based age and 
sex controls. 
  
MATERIALS AND METHODS  
Design, ethics and consent 
We performed a prospective observational cohort study in a tertiary regional 
Intensive Care Unit (ICU) in Geelong, Australia, between February 2010 and 
September 2014. Prior to commencement approval was obtained from the 
Barwon Health Human Research Ethics Committee. Written informed consent 
was obtained prior to inclusion in the study. Participants were compared to 
matched population based controls from the Geelong Osteoporosis Study. 
 
Study population and controls 
Adult (age greater than 20 years) patients admitted to the ICU during the 
study period, and with duration of mechanical ventilation greater than 24 
hours were considered eligible for enrolment in the study. The control 
population was obtained from the Geelong Osteoporosis Study (GOS)35, a 
random population-based sample from the Australian Commonwealth 
Electoral Rolls. Additional details on exclusion criteria and GOS are provided 
in an online data supplement. 
 
Data Collection 
Data collected included demographics, osteoporosis risk factors, information 
relating to critical illness and ICU interventions, ICU and hospital length of 
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stay, survival, discharge destination, quality of life (EQ VAS; EuroQol visual 
analogue scale where own health rated “today” on a scale from 0 “worst 
imaginable health to 100 “best imaginable health”)36, serum biochemistry, 
serum bone formation marker: type 1 N-terminal procollagen, serum bone 
resorption marker: collagen type 1 cross-linked c-telopeptide, and BMD. 
Additional detail on the measurement of serum BTMs and BMD are provided 
in an online data supplement. 
 
Data were collected at three separate time points, ICU baseline (demographic 
data, clinical information, BTMs), post-ICU discharge (BMD) and 1-year post-
ICU discharge (repeat BMD, BTMs, biochemistry, EQ VAS, accommodation). 
Details of operating procedure are provided in Appendix 1. 
 
BMD was presented as an absolute value (g/cm2), annualised percentage 
(difference between BMDs divided by initial BMD calculated as an annualised 
rate), and categorised as normal (T-score > -1.0), osteopenic (T-score -2.5 to 
-1.0), or osteoporotic (T-score <-2.5). The T-score is the number of standard 
deviations above or below the young adult mean, based on WHO criteria 37 
with cut-off values calculated from the Australian reference ranges38,39. 
Fracture risk assessment was performed for each ICU participant who 
completed both BMD studies using the Australian version of the FRAX® 
fracture risk assessment tool, an algorithm developed by the World Health 
Organization (WHO)40 that combines clinical risk factors with or without femur 
BMD to estimate 10-year probability of hip and major osteoporotic fracture.  
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Outcomes  
The primary outcome was annualised percentage change in BMD (lumbar 
spine and dual femoral neck) for the year after ICU discharge compared to 
matched population controls. Secondary outcomes were restricted to the ICU 
cohort and included osteoporosis classification, fracture risk assessment, 
change in BTMs, and analysis of factors associated with change in BMD. 
 
Statistical analysis 
ICU patients who completed both BMD measurements were matched to GOS 
controls by age, sex, and BMI, in a one-to-four fashion using Mahalanobis 
weights, without replacement. Continuously normally distributed data were 
reported as mean (+standard deviation), whereas non-parametric data were 
reported using median (interquartile range [IQR]) or frequency distribution. 
Results were calculated as total and percentage change, with the difference in 
change and 95% CIs calculated using profile likelihood methods, and p-values 
calculated from the likelihood ratio test. The primary outcome was analysed 
using Analysis of Covariance, and a two-sided p-value of 0.05 was considered 
to be statistically significant. Additional information relating to statistical 
analyses are provided in an online data supplement. 
 
RESULTS  
Patient enrolment 
We screened 686 patients and enrolled 138. Of these, 48 (34.8%) withdrew 
before completing the 1-year BMD measurement, and 24 (17.4%) died before 
the 1-year BMD measurement, leaving a final cohort of 66 (47.8%) for 
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analysis (Figure 1). 
 
Baseline characteristics 
Baseline patient characteristics including osteoporosis risk factors, critical 
illness severity, biochemistry, BTMs, key interventions and major outcomes 
are presented in Table 1. Across all three groups, osteoporotic risk factors 
were relatively common with 58 (42.0%) of patients having at least one factor. 
 
In the 66 patients assessed, we found a significant decrease in BMD in the 
year after ICU discharge. This decrease was present at both femoral neck and 
anterior-posterior spine assessment (Table 2). When stratified by sex, a 
significant decrease in BMD was observed in females at both sites, and in 
males at femoral neck only (Table 2). The mean baseline BMD of the ICU 
cohort and controls were similar after matching at both dual femur and 
anterior-posterior spine (supplement table 1). 
 
Primary outcome 
The annual decrease in BMD was significantly greater in the ICU cohort 
compared to matched controls (Table 3). The annual decrease in BMD in the 
year after ICU was 1.48 + 4.37% (anterior-posterior spine) and 1.72 + 4.37% 
(femoral neck), compared to an increase of 0.11+ 1.12% (anterior-posterior 
spine) and a decrease of 0.53 + 1.07% (femoral neck) in controls. This 
represents a difference in annual change in BMD of -1.59% (95% CI -2.18, -
1.01, p < 0.001) at anterior-posterior spine, and -1.20% (95% CI -1.69, -0.70, 
p <0.001) at femoral neck in the ICU cohort compared to controls. This 
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difference was significantly greater in females at both AP spine and femoral 
neck, while in males it was significantly greater at femoral neck only (Table 3). 
 
Secondary outcomes 
Overall, in the year after ICU there was a significant decrease in serum 
collagen type 1 cross-linked c-telopeptide (median 579 ng/L [397,894] vs 306 
ng/L [202,554]; p<0.001), and a significant increase in serum type 1 N-
terminal procollagen (median 31.0 ug/L [20.5, 49.8] vs 44.0 ug/L [31.2,73.9]; 
p=0.04) (Table 4). When stratified by sex and compared to population 
reference levels, the median collagen type 1 cross-linked c-telopeptide levels 
exceeded the 3rd interquartile reference values for females (ICU 654.0 ng/L 
[IQR 478.5, 1165] vs GOS 338 ng/L [IQR 212, 499] and males (ICU 483.0 
ng/L [IQR 382.0, 851.0] vs GOS 328 ng/L [IQR 235, 459]), and returned to 
normal by 1-year.  In contrast, type 1 N-terminal procollagen significantly 
increased but remained within normal levels for males and females (Table 4). 
Over the year from critical illness to follow-up there was a significant increase 
in median vitamin D concentration (43.0 nmol/L [31.0,52.8] vs 55.0 mmol/L 
[46.0,71.0], p<0.001]), elevated median parathyroid hormone levels at 
baseline that did not significantly change (8.1 pmol/L [4.0,13.8] vs 5.4 
pmol/L[4.2,9.4], p=0.15), and a significant increase in median adjusted 
calcium levels (2.0 mmol/L [1.8,2.1]) vs 2.2 {2.2,2.3], p<0.0001). 
 
The percentage of patients with an osteoporotic or osteopenic T-score did not 
change significantly from baseline to one-year after ICU discharge (45.3% vs 
54.7%, p=0.08), although the estimated 10-year fracture risk for both all major 
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fractures (4.85+5.25 vs 5.50+5.52, p<0.001) and hip fractures specifically 
(1.57+2.40 vs 1.79+2.69, p=0.001) significantly increased (Table 4). Finally, 
66.7% of females and 44.1% of males were classified as either osteoporotic 
or osteopenic at 1-year, and the 10-year fracture risk was highest in females. 
 
DISCUSSION  
Key findings 
We performed a prospective observational study in critically ill mechanically 
ventilated patients to measure the changes in BMD and bone turnover 
markers in the year after ICU admission. We found that these patients 
experienced a significant decrease in BMD in the year after ICU admission, 
and this was significantly greater than matched controls. Moreover, they 
carried a significantly increased estimated risk of future fracture. These clinical 
events were associated with a specific pattern of bone turnover markers. This 
pattern was suggestive of increased bone resorption with no commensurate 
response in bone formation during critical illness, followed by normalization of 
resorptive activity but no compensatory increased formation activity a year 
later. 
 
Relationship to previous studies 
To our knowledge, the only previous report of BMD changes after ICU 
described a significant decrease in calcaneal BMD over a 10-day period in 
patients with Acute Respiratory Distress Syndrome (ARDS) compared to 
ventilated non-ARDS patients33 . However, BMD undergoes relatively small 
changes over time of a magnitude similar to measurement error therefore 
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follow-up over longer periods is recommended, making a one year change in 
BMD the standard for interventional research studies41-45. This makes our 
observations relevant to potential intervention in the future.  
Bone turnover markers are an important tool to assess progression of 
osteoporosis, fracture risk, and treatment response 46,47. We measured type 1 
N-terminal procollagen, a bone formation marker synthesized by osteoblasts 
and released during the processing of type I procollagen into collagen, and 
the bone resorption marker collagen type 1 cross-linked c-telopeptide, a 
product of collagen degradation. Both markers correlate with corresponding 
histomorphometric parameters of bone formation and resorption, and have 
been identified as the most promising bone turnover markers by the Joint 
International Bone Markers Standards Working Group 46. We observed a 
change from increased bone resorption during critical illness, to normal bone 
resorption with increasing bone formation over the subsequent year, 
consistent with previous studies reporting increased bone resorption markers 
24,26,29-31,48,49, increased serum osteoclast precursors32, increased bone 
formation, and decreased osteocalcin during critical illness compared to 
controls 26,28,29,49. Overall these findings suggest changes associated with 
critical illness of a magnitude similar to that described in postmenopausal 
females, or metabolic bone disease 29,47,50,51. The interpretation of bone 
turnover markers during critical illness is complex, however as levels are 
affected by a number of factors including age, gender, co-existing disease, 
inflammatory markers, and medications, particularly glucocortocoids 
26,28,49,52,53. This study was unable to analyse these relationships due to its 
limited sample size. 
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Abnormalities in the vitamin D-parathyroid-calcium axis during critical illness, 
and the association with increased illness severity, length of stay, and 
mortality, and the effects of vitamin D supplementation on inflammatory 
markers and outcomes have been described 54-64. We observed a pattern of 
vitamin D insufficiency, increased parathyroid hormone release, and 
hypocalcaemia, during critical illness and normalisation at one-year follow-up. 
Vitamin D deficiency with resultant secondary hyperparathyroidism and 
prolonged immobilization may increase the risk of excessive bone resorption; 
however treating critically ill patients with vitamin D resulted in inconsistent 
effects on bone turnover markers, suggesting that accelerated bone turnover 
is multifactorial 29,48.  
Over half of survivors in our study had BMD in the osteopenic or osteoporotic 
range, higher than local population levels, with the Geelong Osteoporosis 
Study reporting one-fifth of females greater than fifty years of age have BMD 
in the osteopenic range, and 1 in 6 have osteoporosis65. Although the 
proportion of patients with BMD below normal values did not change 
significantly during the year after critical illness, the use of BMD category 
alone has limitations for fracture prediction, as over half of fragility fractures 
arise from the population of individuals with osteopenia, rather than the higher 
risk but smaller population with osteoporosis65-67. This has led to the 
development of fracture risk prevention models that incorporate clinical factors 
and BMD, including the FRAX® fracture risk assessment tool 40. In this 
regard, we observed a significant increase in 10-year probability of hip and 
major osteoporotic fracture in the year after critical illness, consistent with a 
previous observation of increased fracture prevalence in older females 
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following critical illness compared to population-based controls 14. 
Study implications 
This study implies that critical illness is associated with increased bone 
turnover, loss of BMD and increased risk of fragility fractures for up to one year 
after ICU discharge. Such reduced bone mass and increased bone loss in the 
year following critical illness, particularly in female survivors, has not been 
previously described and further implies that such patients may be at particular 
risk. Moreover, in such female patients it also implies that anti-resorptive 
therapy to prevent bone loss, reduce fracture risk, and possibly improve 
survival should be carefully considered. Finally, this study provides a rationale 
for, and essential information towards, the design of pilot interventional trials 
aimed at decreasing bone resorption using BMD at one year as the primary 
outcome. The notion that intervention may be effective is supported by short 
term studies such as a retrospective case series describing a reduction in 
urine N-telopeptide in long-term ventilated patients treated with pamidronate48, 
and a randomised trial of 20 chronic critically ill postmenopausal  females 
reporting  a decrease in serum collagen type 1 cross-linked c-telopeptide and 
increase in osteocalcin with ibandronate compared to placebo68. In addition 
multimodal therapies, including physical therapies and rehabilitation warrant 
investigation in this population69. 
 
Strengths and limitations 
Our study has several strengths. For the first time, we collected detailed 
information, including risk factors, relating to bone mass in a cohort of ICU 
survivors over a prolonged period. This is important as establishing the 
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presence of bone loss after critical illness requires extended observation. We 
measured biomarkers of bone turnover to establish broad relevance to similar 
biomarker studies. For the first time, we followed up a cohort of critically ill 
patients for one year to establish the long-term changes in BMD. Moreover, 
we were able to identify clear and logical changes in BMD over time, which 
were particularly striking in females. Finally, and also for the first time, we 
compared our cohort with age and sex matched controls from a well described 
population-based sample from the same community35. 
 
There are limitations to this study. The loss of over half of the participants 
enrolled due to withdrawal or death made it impossible to develop a robust 
predictive model for specific additional risk factors, and restricts 
generalizability of the findings. However, as expected, female sex was clearly 
associated with greater loss of BMD. Furthermore despite a higher than 
expected rate of death and loss to follow-up, the greater than expected decline 
in BMD resulted in sufficient data to demonstrate differences in the primary 
outcome that were statistically significant and clinically relevant. A larger 
cohort would provide the ability to identify further risk factors, but such 
demanding work can only be justified if studies such as ours provide sufficient 
preliminary data to support its conduct. Comparison of BMD in ICU patients to 
a population-based control group rather than a hospital-based control group 
means we cannot exclude that hospitalisation per se (instead of ICU 
admission alone) may be associated with increased loss of BMD. However, 
the decrease in BMD seen in these patients constitutes the necessary initial 
evidence to conduct such larger studies. Measurement of BMD at ICU 
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discharge and again at one-year does not allow for the observation of non-
linear changes in bone density, for example it is possible an early rapid loss of 
bone density occurred in the months after critical illness, with subsequent 
recovery. However one year change in BMD is the standard for interventional 
research studies41-45. 
 
Also, we have demonstrated an association between critical illness and 
greater decline in BMD, but were unable to separate the effects of pre-critical 
illness factors from critical illness per se. Pre-critical illness chronic disease, 
frailty, and worsening functional trajectory are common in critically ill patients, 
and are associated with trajectory and degree of recovery 70-73. The matching 
of the ICU cohort and the GOS controls by gender and age resulted in similar 
baseline BMDs, refuting the notion that the ICU cohort had lower bone density 
than controls at the time of admission. This may be explained by the 
characteristics of the cohort that completed the study. By definition they had 
100% one-year survival, reported high quality of life, and 95% lived 
independently one-year after ICU discharge. This pattern is most consistent 
with a minimal disability functional trajectory, or a non-frail population 70,71. 
Finally although long-term ICU recovery trials would ideally include 
prospectively collected pre-ICU trajectory data 73-75, critical illness may act as 
a marker for under-diagnosed disease burden irrespective of causality 73.  
 
Conclusions 
We performed a prospective observation study in critically ill mechanically 
ventilated patients to measure the changes in BMD and bone turnover 
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markers in the year after ICU admission. We found that these patients 
experienced a significant decrease in bone density in the year after ICU 
admission compared with controls; carried a significantly increased risk of 
future fracture and had a typical pattern of bone turnover consistent with 
accelerated resorption. Our findings suggest that critical illness may trigger 
increased bone resorption and faster loss of BMD and provide impetus for 
future interventional studies aimed at decreasing such loss. 
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Figure 1: Summary of eligibility, enrolment, and long-term follow-up for study 
procedures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patients fulfilling mechanical 
ventilation criteria b n= 686 
Excluded n= 567 
   Refused or unable to consent n= 290 
   Unable to undergo BMD n=67 
   Active malignancy or metabolic bone disease n=41 
   Treatment limitation / poor prognosis n=84 
   Residence outside catchment area n=81 
 
Enrolled n= 138 
ICU baseline data / BTMs 
 n= 138 
Withdrew from BMD follow-up n=48 
Died n=24 
 
 
1-year BMD n= 66 
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Table 1: Demographic, clinical characteristics, baseline bone turnover 
markers, biochemistry, interventions and outcomes by study completion 
status.  
Variable All (n=138) Assessed (n=66) Not-assessed (n=72) 
Age (yrs) 68.8 [59.8,76.3] 68.7 [61.1,74.5] 70.3 [58.7,77.6] 
Female 69 (50.0) 31 (47.0) 38 (52.8) 
BMI (kg/m
2
) 26.7 [23.8, 30.2]  27.0 [24.3, 30.5]  25.2 [23.1, 27.7]  
Osteoporosis risk factors     
    Parent hip fracture 12 (8.7)  5 (7.6)  7 (9.7)  
    Previous fragility fracture 8 (5.8) 3 (4.5)  5 (6.9)  
    BMI <20 (kg/m
2
) 7 (7.6)  2 (3.0)  5 (6.9)  
    Rheumatoid arthritis 3 (2.2)  2 (3.0)  1 (1.4)  
    Alcohol > 3 units/day 14 (10.1)  4 (6.1)  10 (13.9)  
    Smoker (current) 28 (20.3)  11 (16.7)  17 (23.6)  
    Secondary osteoporosis 8 (5.8)  2 (3.0)  6 (8.3)  
    Corticosteroids (current) 6 (4.3)  2 (3.0)  4 (5.6)  
    Bisphosphonate (current) 12 (8.7)  5 (7.6)  7 (9.7)  
    At least one osteoporosis risk factor 58 (42.0) 23 (34.8) 35 (48.6) 
Co-morbidity    
    Renal 14 (10.1)  5 (7.6)  9 (12.5)  
    Cardiovascular 63 (45.7)  31 (47.0)  32 (44.4)  
    Respiratory 33 (23.9)  15 (22.7)  18 (25.0)  
    Diabetes Mellitus 25 (18.1)  12 (18.2)  13 (18.1)  
Apache III score 69.5 [56.0, 96.5]  66.0 [56.0, 92.8]  72.0 [59.0, 102.2]  
ICU admission category    
     Cardiac failure 21 (15.2)  11 (16.7) 10 (13.9)  
  Cardiothoracic surgery 30 (21.7)  15 (22.7)  15 (20.8)  
  General surgery 27 (19.6)  11 (16.7)  16 (22.2)  
  Other 10 (7.2)  5 (7.6) 5 (6.9)  
  Respiratory failure 11 (8.0)  5 (7.6)  6 (8.3)  
  Sepsis 39 (28.3)  19 (28.8)  20 (27.8)  
Biochemistry and Biomarkers    
    Albumin (g/L) 23.0 [19.0, 27.0]  24.0 [20.0, 28.0]  22.0 [18.0, 27.0]  
    Calcium adj (mmol/L) 2.0 [1.8, 2.2]  2.0 [1.8, 2.1]  2.0 [1.8, 2.2]  
    Creatinine (umol/L) 128.5 [89.0, 181.8]  121.0 [85.5, 178.8]  136.5 [94.0, 198.0]  
    Vitamin D (nmol/L) 41.0 [31.0, 52.0]  43.0 [31.0, 52.8]  40.0 [31.0, 51.0]  
    Phosphate (mmol/L) 0.7 [0.5, 1.0]  0.7 [0.5, 1.0]  0.7 [0.5, 1.1]  
    PTH (pmol/L) 7.0 [3.8, 10.9]  8.1 [4.0, 13.8]  6.3 [3.7, 10.3]  
    CTx (ng/L) 660.0 [418.0, 953.0]  579.0 [396.5, 893.5]  738.0 [487.0, 969.0]  
    P1NP (ug/L) 23.0 [19.0, 27.0]  24.0 [20.0, 28.0]  22.0 [18.0, 27.0]  
Interventions/outcomes    
    Ventilation duration (hrs) 96.0 [47.2, 218.8]  87.0 [48.0, 144.0]  117.5 [47.5, 283.2]  
    Corticosteroid 47 (34.3)  21 (32.3)  26 (36.1)  
    CRRT  28 (20.3) 11 (16.7)  17 (23.6)  
    ICU LOS (days) 7.0 [4.2, 13.0]  6.5 [4.0, 9.0]  7.5 [5.0, 15.0]  
    Hospital LOS (days) 19.0 [12.0, 31.8]  16.5 [11.0, 31.0]  21.5 [12.0, 32.0]  
    ICU survival 129 (93.5)  66 (100) 63 (87.5)  
    Hospital survival 124 (89.9)  66 (100) 58 (80.6)  
1-year status    
    Survival 114 (82.6) 66 (100) 48 (66.7) 
    Living at home - 60 (95.2%)  - 
    EQ VAS - 80 [70, 90] - 
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1. Data are shown as mean (+standard deviation), median [interquartile range] or number (%). 
2. Abbreviations: BMI (Body Mass index), APACHE = acute physiology and chronic health 
evaluation; CRRT (continuous renal replacement therapy), LOS (length of stay), PTH = 
parathyroid hormone, CTX = collagen type 1 cross-linked c-telopeptide, P1NP = type 1 N-
terminal procollagen 
3. Reference ranges: vitamin D (<25nmol/L = deficient, 25-50 nmol/L insufficient, >50 nmol/L 
sufficient), PTH (range 1.6-6.9 pmol/L
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Table 2: Changes in bone mineral density at 1-year follow-up after critical 
illness 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Data are shown as mean (+standard deviation), 
2. Abbreviations: BMD = bone mineral density, AP = anteroposterior. 
3. 35 males completed both AP spine BMDs, 34 completed both femur BMDs. 31 females 
completed both AP spine BMDs, 30 completed both femur BMDs. 
 
 
Table 3: Annualised change in bone mineral density after critical illness 
compared to matched Geelong Osteoporosis Study controls 
 
Variable ICU
 
GOS Difference (95% CI) P-value 
All   (n=66)
 #
  (n=256)     
   Total change AP spine -0.018 (0.055) 0.001 (0.013) -0.019 (-0.026, -0.012) < 0.001 
   Percent change AP spine -1.48 (4.37) 0.11 (1.12) -1.59 (-2.18, -1.01) < 0.001 
   Total change Femur  -0.016 (0.032) -0.005 (0.010) -0.011 (-0.016, -0.007) < 0.001 
   Percent change Femur -1.72 (3.43) -0.53 (1.07) -1.20 (-1.69, -0.70) < 0.001 
Female
 
(n=31)
3 
(n=120) 
  
   Total change AP spine -0.035 (0.050) -0.002 (0.012) -0.033 (-0.042, -0.023) < 0.001 
   Percent change AP spine -2.85 (4.05) -0.18 (1.08) -2.67 (-3.49, -1.86) < 0.001 
   Total change Femur  -0.018 (0.037) -0.006 (0.008) -0.013 (-0.020, -0.005) 0.001 
   Percent change Femur -1.96 (4.03) -0.65 (0.98) -1.31 (-2.10, -0.51) 0.001 
Male (n=35)
3 
(n=136) 
  
   Total change AP spine -0.003 (0.055) 0.005 (0.014) -0.007 (-0.018, 0.003) 0.16 
   Percent change AP spine -0.28 (4.34) 0.36 (1.10) -0.64 (-1.45, 0.17) 0.12 
   Total change Femur  -0.015 (0.027) -0.004 (0.011) -0.010 (-0.016, -0.005) 0.001 
   Percent change Femur -1.52 (2.85) -0.42 (1.13) -1.10 (-1.71, -0.49) < 0.001 
 
1. Data are shown as mean (+standard deviation) 
2. Abbreviations: ICU = Intensive Care Unit, GOS = Geelong Osteoporosis Study, BMD = bone 
mineral density, AP = anteroposterior. 
3. 35 males completed both AP spine BMDs, 34 completed both femur BMDs. 31 females 
completed both AP spine BMDs, 30 completed both femur BMDs. 
 
  
BMD (g/cm2) Baseline 1-year P-value 
All (n=66)    
   Dual Femur  0.958 (0.192) 0.940 (0.193) < 0.001  
   AP Spine  1.226 (0.232) 1.205 (0.241) 0.007 
Female (n=31)
3 
   
   Dual Femur  0.892 (0.165) 0.872 (0.161) 0.02 
   AP Spine  1.183 (0.223) 1.142 (0.223) 0.001  
Male (n=35)
3 
   
   Dual Femur  1.015 (0.197) 0.999 (0.202) 0.002 
   AP Spine  1.264 (0.236) 1.260 (0.246) 0.74 
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Table 4: Changes in biochemistry and bone turnover markers, T-score, and fracture risk, at 1-year follow-up after critical illness  
 
 All (n=66) Female cohort (n=31) Male cohort (n=35) 
Variable  Baseline 1-year P-value Baseline 1-year P-value Baseline 1-year P-value 
Biochemistry and BTMs
3
          
    Calcium adj (mmol/L) 2.0 [1.8, 2.1]  2.2 [2.2, 2.3]  < 0.001  2.0 [1.7, 2.2]  2.3 [2.2, 2.4]  0.001  2.0 [1.9, 2.1]  2.2 [2.2, 2.3]  < 0.001  
    Creatinine (umol/L) 121 [86, 179]  91 [77, 116]  < 0.001  119 [84, 203]  78.0 [67.0, 92.0]  < 0.001  126 [99, 165]  100 [88, 120]  < 0.001  
    Vitamin D (nmol/L) 43.0 [31.0, 52.8]  55.0 [46.0, 71.0]  < 0.001  47.0 [33, 55]  55.0 [48.0, 69.0]  0.02 37.0 [30.0, 49.5]  53.5 [39.5, 74.5]  0.003 
    Phosphate (mmol/L) 0.7 [0.5, 1.0]  1.1 [1.0, 1.2]  0.002  0.7 [0.4, 1.0]  1.1 [1.0, 1.3]  0.04 0.7 [0.6, 0.9]  1.1 [0.9, 1.2]  0.03 
    PTH (pmol/L) 8.1 [4.0, 13.8]  5.4 [4.2, 9.4]  0.15  6.9 [2.9, 11.4]  5.1 [4.5, 8.2]  0.58 8.3 [5.2, 14.4]  7.0 [3.8, 10.4]  0.10 
    CTx (ng/L) 579 [397, 894]  306 [202, 554]  < 0.001  654 [479, 1165]  315 [162, 592]  0.001  483 [382, 851]  305 [230, 542]  0.002 
    P1NP (ug/L) 31.0 [20.5, 49.8]  44.0 [31.2, 73.8]  0.04 29.0 [17.5, 46.0]  47.0 [35.0, 77.2]  0.10 32.0 [23.0, 58.0]  41.0 [29.2, 69.8]  0.11 
Dual Femur T-score
4
          
  Osteoporosis/osteopenia 29 (45.3) 35 (54.7) 
0.08 
17 (56.7) 20 (66.7) 
0.37 
12 (35.3) 15 (44.1) 
0.25 
   Normal 35 (54.7) 29 (45.3) 13 (43.3) 10 (33.3) 22 (64.7) 19 (55.9) 
FRAX
®
 10-year risk
4
          
    Major fracture 4.85 (5.25) 5.20 (5.52) <0.001 6.81 (6.83)  7.34 (7.17)  0.004  3.12 (2.26)  3.31 (2.29)  < 0.001  
    Hip fracture 1.57 (2.40) 1.79 (2.69) 0.001 2.13 (3.12)  2.47 (3.53)  0.01  1.07 (1.39)  1.19 (1.43)  < 0.001  
1. Data are shown as mean (+standard deviation), median [interquartile range] or number (%) 
2. Abbreviations: BTM = bone turnover markers, BMD = Bone Mineral Density, PTH = parathyroid hormone, CTX = collagen type 1 cross-linked c-telopeptide, P1NP = type 1 
N-terminal procollagen, FRAX
®
=Fracture risk assessment tool. 
3. GOS Reference Values
76
: Female median P1NP 37ug/L (IQR 26, 51 ug/), CTx 338 ng/L (IQR 212, 499 ng/L), male median P1NP 37ug/L (IQR 27, 49 ug/L), CTx 328 ng/L 
(IQR 235, 459 ng/L)  
4. Reference ranges: vitamin D (<25nmol/L = deficient, 25-50 nmol/L insufficient, >50 nmol/L sufficient), PTH (range 1.6-6.9 pmol/L) 
5. 34 males completed both femur BMDs, 30 females completed both femur BMD 
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Appendix / Supplement Files 
 
Supplementary Methods 
Exclusion criteria: Exclusion criteria included active malignancy, existing 
neurological illness with impaired weight bearing, inability to lie flat, metabolic 
bone disease, pregnancy, weight greater than 120 kilograms, and considered 
unlikely to survive by the treating intensivist. Patients who had multiple ICU 
admissions during the study period were included for their first ICU admission 
only. Patients not enrolled in the study by day 7 of mechanical ventilation 
were no longer considered for inclusion in the study 
 
Geelong Osteoporosis Study description: The Geelong Osteoporosis Study is 
a random population-based sample from the Australian Commonwealth 
Electoral Rolls recruited between 1993 and 1997 (women) and 2003 to 2008 
(men), for a geographically well defined region, surrounding Geelong, in 
south-eastern Australia called the Barwon Statistical Division. As voting is 
compulsory in Australia, the electoral roll provides a comprehensive listing of 
adults (age > 18 years). Age-stratified random samples of 1494 women (age 
range 20-94 years) and 1540 men (age range 20-97 years) were enrolled, 
with a minimum of 100 in each 5-year age stratum between ages 20 and 69, 
and a minimum of 200 in the age 70-79 year group, and the over 80 year 
group. In this control population, BMD measurements are performed second 
yearly in the female cohort and five yearly in the male cohort.  
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Bone mineral density and serum bone turnover marker measurement 
description: BMD was measured by dual energy x-ray absorptiometry (DXA) 
(Lunar; GE Healthcare, Madison, Wis, USA), at the proximal femur and 
lumbar spine. Short-term precision in vivo was 1.6% for the femoral neck and 
0.6% for the lumbar spine1. The serum bone turnover markers collagen type 1 
cross-linked c-telopeptide and type 1 N-terminal procollagen were collected 
the morning after enrolment with routine early morning blood tests, and 
measured using the automated Roche Modular Analytics E170 analyser. 
Serum collagen type 1 cross-linked c-telopeptide limit of detection was 10 
ng/L with inter-assay coefficient of variations (CVs) of 6.5% at 361 ng/L, 3.8% 
at 816 ng/L and 3.4% at 3304 ng/L (n = 10).  Serum type 1 N-terminal 
procollagen inter-assay CVs were 4.9% at 73 µg/L, 2.6% at 392 µg/L, and 
2.1% at 768 µg/L (n = 10) with a limit of detection of 5 µg/L. Bone turnover 
markers were compared to reference ranges derived from an Australian 
population sample2.   
 
Statistical analysis description: ICU patients who completed both BMD 
measurements were matched to GOS controls by age, sex, and BMI, in a 
one-to-four fashion using Mahalanobis weights, without replacement. 
Mahalanobis weighting was chosen to account for correlation 3.  The average 
treatment effect for those participants admitted to the ICU was estimated via 
linear regression including the covariates used for matching, an indicator 
variable for whether the participant was admitted to the ICU or was a (GOS) 
population control, and a random effect to account for correlation induced by 
the matching. Ninety-five percent confidence intervals (95% CIs) were 
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calculated for the difference by profile likelihood, with p-values from the 
likelihood ratio test. 
 
The annual decline in lumbar spine in the GOS population is normally 
distributed, with a standard deviation of 0.06% at the lumbar spine in males, 
and 0.25% at the lumbar spine in females. In the absence of any existing data 
describing long-term BMD changes following critical illness, a global effect 
size of 50% of one standard deviation was chosen to be clinically significant 
as it equates to a 12% difference across the range of each variable. In order 
to have a 90% power (2-sided p-value of 0.05) to detect an effect size of 50% 
of one standard deviation, 84 subjects are required. Allowing for potential 
deaths (20%) and dropouts (20%), 138 subjects were recruited. 
 
Data were analysed using R version 3.1.3 (R Core Team 2015) and a two-
sided p-value of 0.05 was considered to be statistically significant. 
Continuously normally distributed data were reported as mean (+standard 
deviation), whereas non-parametric data were reported using median (IQR) or 
frequency distribution. The primary outcome was analysed using Analysis of 
Covariance. Results were calculated as total and percentage change, with the 
difference in change and 95% CIs calculated using profile likelihood methods, 
and p-values calculated from the likelihood ratio test.  
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 Appendix 1: Study operating procedures 
 
 
Supplement Table 1: Comparison of baseline demographics of ICU and 
GOS cohorts before and after matching  
 
Variable  ICU (n=64)
2 
Before Matching After Matching 
GOS (n=3277) SMD GOS (n=256) SMD 
Female  30 (47%) 1533 (47%)  0.53 120 (47%) 0.00 
Age  65.03 (+ 13.65) 51.80 (16.44)  9.62 65.00 (+ 13.54) 0.02 
BMI  27.82 (+ 5.07) 26.98 (4.41) 1.63 27.42 (+ 4.34) 0.77 
Weight  77.00 (+ 16.02) 77.65 (13.84) 0.40 76.88 (+ 13.37) 0.07 
Height  1.66 (+ 0.10) 1.70 (0.09) 3.26 1.67 (+ 0.09) 1.2 
AP Spine baseline BMD 1.225 (+ 0.226) 1.25 (0.18) 1.23 1.229 (+ 0.220) 0.17 
Dual Femur baseline BMD 0.958 (+ 0.190) 0.98 (0.15) 1.25 0.928 (+ 0.158) 1.56 
 
1. Data are shown as mean (+SD), median [IQR] or no.(%) or standardised mean difference 
(SMD) 
2. 64 participants had both spine and femur BMD measurements performed at follow-up 
 
 
 
 
 
Softer Study Procedures 
>24 hrs to <168 hrs duration of mechanical ventilation 
Enrolment Inclusion criteria met, consent obtained 
Study procedures 
Baseline and demographic data 
Biochemistry and BTM (serum PINP, CTx, Vit D, PTH, 
albumin, calcium, phosphate, creatinine) 
ICU discharge (ICU discharge to 1-month) 
Study procedure BMD #1 
1 year follow-up (1 year post-ICU discharge) 
Study procedure 
Contact participant 
BMD #2 
Biochemistry and BTMs (serum PINP, CTx, vitamin D, PTH, 
albumin, calcium, phosphate, creatinine) 
Questionnaire (EQ VAS) 
Vitamin D / calcium / anti-resorptive therapy will be offered to participants in accordance with current 
guidelines and review of results and risk factors by an endocrinologist 
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